Skip to content
Screener

Discontinued — last reported Q3 '24

G&A at other companies

Omada Health logo
Omada HealthOMDA
$15.73M+27.8%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$20.98M+219%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%
Savara logo
SavaraSVRA
$15.57M+68.4%
AdaptHealth logo
AdaptHealthAHCO
$95.91M+10.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$37.59M-8.4%

Segments

By segment

See full
All Other Segments$17.39M+3.9%

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.32B+25.9%
Enterprise value$1.28B+27.4%
P/S3.4×-0.1×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Mannkind’s 10-Q, filed November 7, 2024.

Filed
Nov 7, 2024
Fiscal quarter
Q3 FY2024
Calendar quarter
Q3 2024
Accession
0000950170-24-123296
Line itemThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Cost of revenue – collaborations and services14,82610,25944,37729,955
Research and development12,9269,98934,75522,047
Selling13,09313,44036,18940,752
General and administrative10,82310,53834,16833,027
Loss (gain) on foreign currency transaction2,454(2,065)526(860)
Total expenses57,31946,156162,636139,670
Income from operations12,7605,09746,092820
Other income (expense):

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's G&A?
Mannkind (MNKD) reported G&A of $10.82M in Q3 2024.
How has Mannkind's G&A changed year-over-year?
Mannkind's G&A increased by 2.7% year-over-year, from $10.54M to $10.82M.
What is the long-term trend for Mannkind's G&A?
Over 2 years (2021 to 2023), Mannkind's G&A has grown at a 15.5% compound annual growth rate (CAGR), from $31.89M to $42.54M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Mannkind's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude